10 results about "Nicotine replacement" patented technology

Tobacco products comprising smokeless tobacco products and active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel are disclosed. Nicotine replacement therapies comprising active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel. The active ingredient may reduce or eliminate sensory irritation arising due to use of the product. Analgesic compositions comprising active ingredients. Methods of reducing taste and sensory irritation by employing an active ingredient.

Tobacco products comprising smokeless tobacco products and active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel are disclosed. Nicotine replacement therapies comprising active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel. The active ingredient may reduce or eliminate sensory irritation arising due to use of the product. Analgesic compositions comprising active ingredients. Methods of reducing taste and sensory irritation by employing an active ingredient.

The present application relates to the technical field of electronic atomization, and specifically relates to a nicotine replacement liquid preparation, and a preparation method therefor and the use thereof. In the nicotine replacement liquid preparation provided in the present application, the raw material components of the nicotine replacement liquid preparation comprise an additive capable of simulating the throat-hit sensation of nicotine, an additive capable of simulating the head-rush sensation of nicotine, and an atomization solvent. The additive capable of simulating the throat-hit sensation of nicotine is selected from at least one of piperine and 6-methylnicotine; and the additive capable of simulating the head-rush sensation of nicotine is selected from at least one of cytisine, magnolol and 6-methylnicotine. The nicotine replacement liquid preparation of the present application simulates the head-rush sensation and throat-hit sensation brought about by nicotine, enhances the head-rush sensation and throat-hit sensation of a nicotine-free atomization preparation, and improves the sense of satisfaction of a user, thereby achieving the aim of relieving addiction physiologically. Moreover, the toxicity and addictiveness of the nicotine replacement liquid preparation are both much lower than nicotine, such that damages to health can be reduced.

The invention discloses atomized liquid, an atomizer and an electronic atomization device. The atomized liquid comprises 65 wt%-99.65 wt% of a solvent, 0.1 wt%-5 wt% of a nicotine substitute and 0.25 wt%-30 wt% of a flavoring agent, the nicotine substitute is selected from at least one of 6-alkyl nicotine and a salt of 6-alkyl nicotine, and the alkyl group has 1-4 carbon atoms. The irritation of the substitute of nicotine in the atomized liquid is reduced, the taste is close to that of traditional tobacco, and the satisfaction is improved.

The invention relates to the technical field of electronic atomization, in particular to a nicotine substitute liquid preparation and a preparation method and application thereof. The invention provides a nicotine substitution liquid preparation. The nicotine substitution liquid preparation comprises the following raw material components: a nicotine throat hitting feeling simulation additive, a nicotine head feeling simulation additive and an atomization solvent, the nicotine throat hitting feeling simulation additive is selected from at least one of piperine and 6-methyl nicotine; the nicotine head feeling simulation additive is selected from at least one of cytisine, magnolol and 6-methyl nicotine. The nicotine replaces a liquid preparation to simulate the feeling of feeling on the head and the feeling of hitting the throat caused by the nicotine, the feeling of feeling on the head and the feeling of hitting the throat of the nicotine-free atomized preparation are improved, the satisfaction of a user is improved, the aim of physiologically relieving addiction is achieved, meanwhile, the toxicity and addiction of the nicotine-free atomized preparation are far lower than those of the nicotine, and health damage can be reduced.

This application belongs to the field of food or pharmaceutical technology, specifically relating to a lozenge and its preparation method. The lozenge includes a granular composition comprising the following components: an active substance, a cationic resin, cationic salt sustained-release granules, and a filler; wherein the active substance includes at least one of the following: nicotine or a nicotine derivative. This solution incorporates cationic salt sustained-release granules into the lozenge, which not only effectively prevents the rapid dissolution of the cationic salt, allowing it to maintain an effective concentration in the oral cavity for a prolonged period, thus facilitating sufficient contact with the cationic resin to ensure nicotine replacement, but also regulates the release rate of the cationic salt, thereby regulating the nicotine replacement rate.

A synthetic nicotine substitute for use in a variety of delivery systems, particularly in electronic nicotine delivery systems, such as atomizers, electronic cigarettes, combustion, heat-not-burn products, oral or nasal nicotine delivery systems. (S)-6-methylnicotine, also known as (S)-2-methyl-5-(1-methylpyrrolidine-2-yl) pyridine, is a derivative of nicotine, and the 6-site of the pyridine ring of the (S)-6-methylnicotine is substituted by methyl. Preliminary experimental data show that the efficacy of (S)-6-methylnicotine is about 4-5 times (by weight) of nicotine, the (S)-6-methylnicotine can take effect more quickly, and the nicotine desire can be controlled or met more effectively. The carboxylate is also applicable. The enhanced efficacy enables people to alleviate nicotine craving faster and more effectively with a lower dose, and produces a subjective satisfaction to meet the smoking addiction. This enhanced pharmacological efficacy allows for the use of smaller amounts of active ingredients compared to synthetic nicotine formulations, among other potential benefits.

The present disclosure generally relates to a treatment method for helping a subject quit smoking, the method comprising at least one step of administering to the subject an effective dose of an aqueous solution of protein-enriched tobacco leaf extract while the subject continues to smoke freely.Optionally, the second step comprises providing the subject with at least one product capable of controlling nicotine withdrawal symptoms, such as a nicotine agonist or partial agonist, and / or a nicotine substitute, by one or several optional complementary administrations.The present disclosure also relates to a kit comprising a protein-enriched tobacco leaf extract and at least one product capable of controlling nicotine withdrawal symptoms, such as a nicotine agonist or partial agonist, and / or a nicotine substitute.

The present disclosure is generally directed to a method of treatment to aid in smoking cessation of a subject, comprising: at least one step during which an effective dose of an aqueous solution of a protein-rich tobacco extract is administered to the subject during which the subject continues to freely smoke; and optionally a second step during which at least one product capable of controlling the symptom of nicotine withdrawal, such as a nicotine agonist or a nicotine partial agonist, and / or a nicotine substitute, is administered to the subject optionally in a supplemental manner once or several times. The present disclosure also relates to a kit comprising a protein-rich tobacco extract and at least one product capable of controlling nicotine withdrawal symptoms of nicotine, such as a nicotine agonist or a nicotine partial agonist and / or a nicotine substitute.